| Literature DB >> 29533771 |
Brent E Fitzwalter1, Christina G Towers1, Kelly D Sullivan2, Zdenek Andrysik1, Maria Hoh1, Michael Ludwig1, Jim O'Prey3, Kevin M Ryan3, Joaquin M Espinosa2, Michael J Morgan1, Andrew Thorburn4.
Abstract
Macroautophagy (autophagy) is intimately linked with cell death and allows cells to evade apoptosis. This has prompted clinical trials to combine autophagy inhibitors with other drugs with the aim of increasing the likelihood of cancer cells dying. However, the molecular basis for such effects is unknown. Here, we describe a transcriptional mechanism that connects autophagy to apoptosis. The autophagy-regulating transcription factor, FOXO3a, is itself turned over by basal autophagy creating a potential feedback loop. Increased FOXO3a upon autophagy inhibition stimulates transcription of the pro-apoptotic BBC3/PUMA gene to cause apoptosis sensitization. This mechanism explains how autophagy inhibition can sensitize tumor cells to chemotherapy drugs and allows an autophagy inhibitor to change the action of an MDM2-targeted drug from growth inhibition to apoptosis, reducing tumor burden in vivo. Thus, a link between two processes mediated via a single transcription factor binding site in the genome can be leveraged to improve anti-cancer therapies.Entities:
Keywords: CRISPR/Cas9; FOXO3a; MDM2; PUMA; apoptosis; autophagy; chloroquine; homeostasis; nutlin; p53
Mesh:
Substances:
Year: 2018 PMID: 29533771 PMCID: PMC5866042 DOI: 10.1016/j.devcel.2018.02.014
Source DB: PubMed Journal: Dev Cell ISSN: 1534-5807 Impact factor: 12.270